2017-2023年波兰弗罗茨瓦夫接触前预防疗法(PrEP)使用期间的艾滋病毒偶发感染情况:真实体验。

IF 3.6 3区 医学 Q2 INFECTIOUS DISEASES
Bartosz Szetela, Karol Serwin, Mateusz Bozejko, Aleksander Zinczuk, Kamila Zielinska, Lukasz Lapinski, Aleksandra Szymczak, Anna Urbanska, Jacek Gąsiorowski, Miłosz Parczewski
{"title":"2017-2023年波兰弗罗茨瓦夫接触前预防疗法(PrEP)使用期间的艾滋病毒偶发感染情况:真实体验。","authors":"Bartosz Szetela, Karol Serwin, Mateusz Bozejko, Aleksander Zinczuk, Kamila Zielinska, Lukasz Lapinski, Aleksandra Szymczak, Anna Urbanska, Jacek Gąsiorowski, Miłosz Parczewski","doi":"10.1136/sextrans-2024-056329","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The efficacy of pre-exposure prophylaxis (PrEP) relies on adherence to effective regimens. As data on real-life PrEP roll-out and efficacy from Central and Eastern Europe are scarce, we explored the HIV incident infections among PrEP users in an observational cohort in Poland.</p><p><strong>Methods: </strong>A cohort of 887 men having sex with men (MSM) on generic emtricitabine/tenofovir disoproxil (FTC/TDF) were followed for a cumulative 2587 person years (PY). HIV infection was confirmed using molecular and immunoassays, with subtype and genotyping performed at diagnosis. For phylogenetic analysis, we used 2087 HIV-1 A6 partial <i>pol</i> sequences from Poland as background.</p><p><strong>Results: </strong>Nine (1%) PrEP users acquired HIV during the follow-up period. The estimated HIV incidence was 0.347 per 100 PY, with a relative risk reduction of 90.9%. All users who acquired HIV were cisgender white MSM of European origin (median age: 35.5 years). The majority (eight out of nine) used PrEP on demand (ie, 2-1-1 schedule), with one using PrEP only before receptive and not insertive sexual contacts and seven skipping the double dose. Infections occurred due to inadequate PrEP dosing. In five (55.6%) and four (44.4%) users, subtypes B and A6 were acquired, respectively, with no drug resistance. Each of the four A6 sub-subtypes belonged to distinct clusters. Three of them had distinct regional origins within Poland and one in Ukraine. Users were started on tenofovir alafenamide/emtricitabine/bictegravir at a median of 10.5 days from diagnosis and reached undetectable viral load (<50 copies/mL) at a median of 63 days.</p><p><strong>Conclusions: </strong>Overall, FTC/TDF PrEP was very effective, with failures occurring due to suboptimal adherence to on-demand dosing. Effective communication of HIV-related risks and clear instructions on how to use on-demand PrEP without missing doses should be provided to PrEP users. Despite the lack of transmitted drug resistance, we noted a higher number of infections with the A6 subtype and independent lineage introductions.</p>","PeriodicalId":21624,"journal":{"name":"Sexually Transmitted Infections","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIV incident infections during pre-exposure prophylaxis (PrEP) use in Wroclaw, Poland, 2017-2023: a real-life experience.\",\"authors\":\"Bartosz Szetela, Karol Serwin, Mateusz Bozejko, Aleksander Zinczuk, Kamila Zielinska, Lukasz Lapinski, Aleksandra Szymczak, Anna Urbanska, Jacek Gąsiorowski, Miłosz Parczewski\",\"doi\":\"10.1136/sextrans-2024-056329\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The efficacy of pre-exposure prophylaxis (PrEP) relies on adherence to effective regimens. As data on real-life PrEP roll-out and efficacy from Central and Eastern Europe are scarce, we explored the HIV incident infections among PrEP users in an observational cohort in Poland.</p><p><strong>Methods: </strong>A cohort of 887 men having sex with men (MSM) on generic emtricitabine/tenofovir disoproxil (FTC/TDF) were followed for a cumulative 2587 person years (PY). HIV infection was confirmed using molecular and immunoassays, with subtype and genotyping performed at diagnosis. For phylogenetic analysis, we used 2087 HIV-1 A6 partial <i>pol</i> sequences from Poland as background.</p><p><strong>Results: </strong>Nine (1%) PrEP users acquired HIV during the follow-up period. The estimated HIV incidence was 0.347 per 100 PY, with a relative risk reduction of 90.9%. All users who acquired HIV were cisgender white MSM of European origin (median age: 35.5 years). The majority (eight out of nine) used PrEP on demand (ie, 2-1-1 schedule), with one using PrEP only before receptive and not insertive sexual contacts and seven skipping the double dose. Infections occurred due to inadequate PrEP dosing. In five (55.6%) and four (44.4%) users, subtypes B and A6 were acquired, respectively, with no drug resistance. Each of the four A6 sub-subtypes belonged to distinct clusters. Three of them had distinct regional origins within Poland and one in Ukraine. Users were started on tenofovir alafenamide/emtricitabine/bictegravir at a median of 10.5 days from diagnosis and reached undetectable viral load (<50 copies/mL) at a median of 63 days.</p><p><strong>Conclusions: </strong>Overall, FTC/TDF PrEP was very effective, with failures occurring due to suboptimal adherence to on-demand dosing. Effective communication of HIV-related risks and clear instructions on how to use on-demand PrEP without missing doses should be provided to PrEP users. Despite the lack of transmitted drug resistance, we noted a higher number of infections with the A6 subtype and independent lineage introductions.</p>\",\"PeriodicalId\":21624,\"journal\":{\"name\":\"Sexually Transmitted Infections\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sexually Transmitted Infections\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/sextrans-2024-056329\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sexually Transmitted Infections","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/sextrans-2024-056329","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

目的:暴露前预防(PrEP)的疗效取决于对有效方案的依从性。由于中欧和东欧关于PrEP的实际推广和疗效的数据很少,我们在波兰的一个观察队列中探讨了PrEP使用者中的HIV事件感染。方法:对887名服用恩曲他滨/替诺福韦二氯吡酯(FTC/TDF)的男男性行为者(MSM)进行了累计2587人年(PY)的随访。通过分子和免疫分析确认HIV感染,并在诊断时进行亚型和基因分型。为了进行系统发育分析,我们使用来自波兰的2087个HIV-1 A6部分pol序列作为背景。结果:9名(1%)PrEP使用者在随访期间感染了HIV。估计艾滋病毒感染率为0.347 / 100 PY,相对风险降低90.9%。所有感染艾滋病毒的人都是欧洲血统的顺性白人男男性行为者(中位年龄:35.5岁)。大多数人(9人中有8人)按需使用PrEP(即2-1-1计划),其中1人仅在接受性接触而非插入性接触之前使用PrEP, 7人不使用双倍剂量。感染的发生是由于PrEP剂量不足。5名(55.6%)和4名(44.4%)使用者分别获得B和A6亚型,无耐药。4种A6亚型均属于不同的聚类。其中三个在波兰有明显的地区起源,一个在乌克兰。患者在诊断后10.5天开始使用替诺福韦-阿拉那胺/恩曲他滨/比替他韦,病毒载量无法检测到(结论:总体而言,FTC/TDF PrEP非常有效,失败是由于对按需给药的依从性不理想。应向PrEP使用者提供有关艾滋病毒相关风险的有效沟通,并明确说明如何按需使用PrEP而不遗漏剂量。尽管缺乏传播性耐药,但我们注意到A6亚型和独立谱系引入的感染数量较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
HIV incident infections during pre-exposure prophylaxis (PrEP) use in Wroclaw, Poland, 2017-2023: a real-life experience.

Objectives: The efficacy of pre-exposure prophylaxis (PrEP) relies on adherence to effective regimens. As data on real-life PrEP roll-out and efficacy from Central and Eastern Europe are scarce, we explored the HIV incident infections among PrEP users in an observational cohort in Poland.

Methods: A cohort of 887 men having sex with men (MSM) on generic emtricitabine/tenofovir disoproxil (FTC/TDF) were followed for a cumulative 2587 person years (PY). HIV infection was confirmed using molecular and immunoassays, with subtype and genotyping performed at diagnosis. For phylogenetic analysis, we used 2087 HIV-1 A6 partial pol sequences from Poland as background.

Results: Nine (1%) PrEP users acquired HIV during the follow-up period. The estimated HIV incidence was 0.347 per 100 PY, with a relative risk reduction of 90.9%. All users who acquired HIV were cisgender white MSM of European origin (median age: 35.5 years). The majority (eight out of nine) used PrEP on demand (ie, 2-1-1 schedule), with one using PrEP only before receptive and not insertive sexual contacts and seven skipping the double dose. Infections occurred due to inadequate PrEP dosing. In five (55.6%) and four (44.4%) users, subtypes B and A6 were acquired, respectively, with no drug resistance. Each of the four A6 sub-subtypes belonged to distinct clusters. Three of them had distinct regional origins within Poland and one in Ukraine. Users were started on tenofovir alafenamide/emtricitabine/bictegravir at a median of 10.5 days from diagnosis and reached undetectable viral load (<50 copies/mL) at a median of 63 days.

Conclusions: Overall, FTC/TDF PrEP was very effective, with failures occurring due to suboptimal adherence to on-demand dosing. Effective communication of HIV-related risks and clear instructions on how to use on-demand PrEP without missing doses should be provided to PrEP users. Despite the lack of transmitted drug resistance, we noted a higher number of infections with the A6 subtype and independent lineage introductions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Sexually Transmitted Infections
Sexually Transmitted Infections 医学-传染病学
CiteScore
5.70
自引率
8.30%
发文量
96
审稿时长
4-8 weeks
期刊介绍: Sexually Transmitted Infections is the world’s longest running international journal on sexual health. It aims to keep practitioners, trainees and researchers up to date in the prevention, diagnosis and treatment of all STIs and HIV. The journal publishes original research, descriptive epidemiology, evidence-based reviews and comment on the clinical, public health, sociological and laboratory aspects of sexual health from around the world. We also publish educational articles, letters and other material of interest to readers, along with podcasts and other online material. STI provides a high quality editorial service from submission to publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信